Background. Optimizing colistin dosing should translate to improved patient outcomes. Methods. We used data from 2 prospective cohort studies performed between 2006 and 2009 and between 2012 and 2015. In the latter period, a new policy of high-dose colistin (9 million international units [MIU] loading dose followed by 9 MIU daily for normal renal function) was introduced in 2 participating hospitals. We included adult inpatients with invasive infections caused by carbapenem-resistant gram-negative bacteria treated with colistin. Our primary exposure variable was colistin dose, dichotomized to highdose vs other regimens. The primary outcome was 28-day mortality. We generated a propensity score for high-dose colistin and conducted propensity-adjusted multivariable and matched-cohort analyses for mortality.
Colistin ( polymyxin E) has resurged in the last decade for the treatment of carbapenem-resistant gram-negative bacteria (CRGNB) [1, 2] . Due to their early introduction in the 1940s and 1950s, polymyxins have not undergone the same testing as mandated nowadays, starting from pharmacokinetics (PK) and pharmacodynamics (PD) assays and passing through phase 1-3 clinical studies. Hence, data are scarce regarding colistin's PK/PD and toxicodynamics, which are necessary to establish an effective and safe treatment schedule, especially in critically ill patients.
Recent PK studies have pointed to the colistin dose necessary to achieve a drug level above colistin's breakpoint of 2 mg/L and supported a regimen of 4.5 million international units (MIU) twice daily [3] [4] [5] . This dose is higher than that traditionally used in Europe. A loading dose (of 9 or 12 MIU) has also been suggested to reach therapeutic levels in <24 hours, although the results from PK studies are conflicting [4, 5] . Studies using the low dosing regimens of colistin (around 6 MIU/day) showed inferior outcomes for colistin compared with β-lactams [2] . Whether higher dosing regimens result in better outcomes is unknown.
We conducted a prospective cohort study to examine the association between colistin dosing and clinical outcomes among patients with invasive infections caused by CRGNB.
METHODS
We used data from 2 prospective cohort studies. The first cohort was collected with the intention of comparing colistin vs β-lactams [6] ; we used the data of patients treated with colistin from this cohort. The second was conducted with the specific intention of assessing the efficacy and safety of the new dosing regimen after the colistin dosage policy was changed in participating hospitals. The first study was conducted in Rabin Medical Center, Beilinson Hospital, between April 2006 to August 2009 and the second both in Rabin Medical Center and in Rambam Health Care Campus between August 2012 and July 2015. Both are primary and tertiary care university-affiliated hospitals of 1000 and 942 beds, respectively, in Israel. Both hospitals comprise combined medical and surgical intensive care units of 14 and 18 beds, respectively; bone marrow transplant departments; and cardiac surgery and neurosurgery. The study was conducted in all wards of both hospitals. The same inclusion criteria, data collection methods, and variable and outcome definitions were used in both study periods. In the first study period, colistin was dosed according to the manufacturer's instructions (European preparation) recommending 3-6 MIU of colistin per day, without a loading dose. In the second study period, both hospitals issued revised guidelines for colistin dosing recommending a 9 MIU loading dose followed by 4.5 MIU every 12 hours (1 MIU equivalent to approximately 30 mg colistin base activity).
We included adult inpatients with invasive infections caused by CRGNB resistant to all tested carbapenems (using Clinical and Laboratory Standards Institute 2009 criteria [7] ), susceptible to colistin (minimum inhibitory concentration [MIC] ≤2 mg/L), and treated with colistin for at least 72 hours or until death. We included only patients fulfilling Centers for Disease Control and Prevention diagnostic criteria for invasive infections, including bloodstream infection of any source; hospitalacquired pneumonia and ventilator-associated pneumonia; urinary tract infection; or deep skin, soft tissue, joint, and bone infections [8] . Patients were included in the study only once, for the first infectious episode. We excluded patients included in a randomized controlled trial (RCT) ongoing at the study centers from June 2014 [9] . Patients were identified through a daily report of the microbiology laboratory of all CRGNB and through the pharmacy records of colistin prescriptions. Patients with concomitant carbapenem-susceptible isolates were included only if treated appropriately for the concomitant isolate.
Our exposure variable was colistin dose, primarily dichotomized to high dose vs other, lower, dosing regimens. High dose was defined when a loading dose of 9 MIU was followed by a high maintenance dose. To classify the maintenance dose, we calculated the ratio between the actual maintenance dose administered to the patient and the patient's renal-adjusted target dose, as recommended by Garonzik et al [3] . A ratio >80% was considered per-protocol as high maintenance dose. Because colistin doses changed during treatment, we based the classification of the patient's maintenance dose according to the treatment given in the first 3 days of treatment. In addition, we compared high (>80% of target dose) vs lower maintenance dose regardless of the loading dose, and assessed the impact of the loading dose among patients given a high maintenance dose.
The primary outcome was 28-day all-cause mortality. Secondary outcomes included fever duration, defined as the number of days until 3 consecutive days with temperature <38°C; hospitalization duration from the start of colistin treatment until discharge from hospital for patients discharged alive by day 28; and resistance development, defined as isolation of a new colistin-resistant bacteria (MIC >2 mg/L). Adverse events included nephrotoxicity, diarrhea, Clostridium difficile infection, neuropathy (defined as clinically diagnosed muscle weakness), or seizures unexplained by another cause. Nephrotoxicity was defined as meeting the injury category of risk, injury, failure; loss, end-stage renal disease (RIFLE) or higher, with injury defined as serum creatinine level increased ≥2.0 times or creatinine clearance decreased ≥50% of baseline [10] at day 14 for surviving patients or until death for those dying before day 14. Patients dying before day 14 without renal failure and those on hemodialysis at onset were excluded from the analysis of nephrotoxicity.
We collected additional factors potentially associated with 28-day mortality, including the study period; hospital; patient demographics; background conditions, including the revised Charlson comorbidity index [11] ; sepsis presentation, including the Sequential Organ Failure Assessment (SOFA) score [12] ; laboratory tests including renal function, blood count, and albumin level; devices present at infection onset; appropriateness of empiric antibiotic treatment; and all antibiotics used from onset of treatment until day 28. Appropriate empiric antibiotic treatment was defined as covering antibiotics administered up to 48 hours after the date culture was taken. Combination therapy was defined as an antibiotic in addition to colistin for at least 2 days during the first week from the start of colistin treatment. All data were manually collected from the patients' records, which were paper-based in the first period and electronic in the second.
Dichotomous or categorical variables were compared using the χ 2 test or the Fisher exact test, as appropriate. Continuous variables were compared using the t test for normally distributed variables and the Mann-Whitney U test for skewed variables. Variables found to be significant on univariate analysis (P < .05) were examined for statistical and clinical correlations, and noncorrelated variables were entered into a multivariate logistic regression analysis, in which the dependent variable was 28-day mortality. Multiple imputations were used for a maximum of 37 patients (albumin) for several values to allow their inclusion in the regression model. We forced the exposure variable (colistin regimen) into the final equation. The goodness of fit and predictive ability of the model were examined using the Hosmer-Lemeshow test and the receiver operating characteristic (ROC) curve, respectively. We calculated a propensity score for the high-dose regimen and used it once as a covariate in the multivariate analysis and once to create a propensity-matched cohort. We performed 1:2 (high-dose:other) greedy matching of the nearest propensity score without replacement, with a caliper of 0.3. Subgroup analysis was performed for patients with bacteremia. The sample size was calculated to allow examination of at least 10 covariates in the multivariable analysis other than the exposure variable and the propensity score, and at least 25% of patients receiving high-dose colistin. Analyses were performed using SPSS software, version 23.
RESULTS
Overall, 529 consecutive patients with a first infectious episode fulfilled inclusion criteria. One hundred forty-four patients (all in the second study period) were treated with high-dose colistin and 385 with lower-dose colistin regimens (267 in the first and 118 in the second study period). The median maintenance colistin dose in the high-dose group was 9 MIU/day (interquartile range [IQR], 9-9) vs 4 MIU/day (IQR, 3-6) with other regimens.
Patients treated with high-dose colistin were younger and had less chronic or acute renal failure, leading to lower Charlson and SOFA scores. Acinetobacter baumannii was the most frequent pathogen in both groups. Pneumonias caused by A. baumannii were dominant with high-dose colistin, whereas Klebsiella pneumoniae infections and bacteremias were significantly more frequent in the low-dose group (Supplementary Table 1 ). Colistin MICs, documented only in the second study period, were low (Supplementary Table 1 ). Relevant variables were used to construct the propensity score for high-dose colistin ( Table 1) . The model was highly predictive, with an area under the ROC curve of 0.804 (95% confidence interval [CI], .763-.845).
Risk Factors for Mortality
In the unadjusted analysis, 28-day mortality was 34.7% (50/144) with high-dose colistin vs 42.9% (165/385) in the low-dose group (P = .09). Disregarding the loading dose, mortality was 37.6% (97/258) with a high vs 43.5% (118/271) with a low maintenance dose (P = .164). Among those given a high maintenance dose, mortality was 34.7% (50/144) with a loading dose vs 41.2% (47/114) without (P = .284). Ranking the ratio between the administered to target colistin dose to finer categories showed no consistent trend in death rates for ratios up to 1, but higher mortality (26/47 [55.3%]) with ratios >1 (inadvertent higher than required dosing). Other factors associated with mortality are shown in Table 2 . Neither appropriate empiric antibiotic treatment (overall given to 29.1% [154/529] patients) nor combination therapy was associated with mortality (Table 2) . On propensity score-adjusted multivariate analysis, colistin dosing was not significantly associated with mortality (odds ratio [OR], 1.075 [95% CI, .631-1.833] for high-dose colistin) ( Table 3) . Factors independently associated with mortality included age, female sex, Charlson and SOFA scores, low albumin levels, and low platelet counts. Excluding the propensity score from the analysis did not change results. Disregarding the loading dose resulted in an OR of 1.037 (95% CI, .658-1.634) for death with high maintenance dose.
There was no difference in mortality between the study periods, with 112 of 267 (41.9%) deaths in the first period (lowdose) vs 103 of 262 (39.3%) in the second period (P = .537). The adjusted OR for mortality in the new study period (including the propensity score) was 1.174 (95% CI, .697-1.98).
Among patients with bacteremia, 14 of 32 patients (43.8%) given high-dose colistin died, vs 91 of 175 (52%) given other regimens (unadjusted OR, 0.718 [95% CI, .336-1.533]). Due to sparse data, a multivariable analysis was not performed.
Propensity-Matched Analysis for Mortality
The propensity-matched cohort included 111 patients treated with high-dose colistin and 178 with other regimens. No significant differences between groups were observed for the factors shown in Table 2 
Secondary Outcomes
There were no differences between the high-and lower-dose regimens in 7-and 14-day mortality (Table 4 ). Time to defervescence and to discharge from hospital among survivors was not significantly different, but the trend was not in favor of SOFA score, median (IQR) 6 (4-9) (n = 214) 4 (2-6) (n = 312) <.001
Laboratory tests at treatment onset Sodium, mEq/L, mean ± SD 141.95 ± 7.93 (n = 213) 141 ± 6.07 (n = 308) .119 the high dose. Superinfection rates and acquisition of colistinresistant gram-negative bacteria were less frequent among patients receiving the high dose. A RIFLE score of injury or higher was significantly more frequent with the high-dose maintenance regimen (without a difference between those given or not given a loading dose) (unadjusted OR, 2.121 [95% CI, 1.293-3.481]; n = 396). Higher nephrotoxicity rates were observed with high-dose colistin mainly for RIFLE injury (2 times increase in creatinine; 9.9% with high dose vs 5.7% with low dose) and failure (3 times creatinine or acute rise by at least 0.5-4 mg/dL; 16.7% vs 8.8%). The rate of nephrotoxicity (RIFLE >1) started to rise at ratios >0.66 of the target dose. Seizures, documented in the medical records of 7 of 144 (4.9%) patients receiving high-dose colistin, were significantly more common than with low-dose colistin (4/382 [1%]) (P = .012). Other adverse events were not significantly different.
DISCUSSION
We aimed to demonstrate improved clinical outcomes for patients with invasive infections caused by carbapenem-resistant bacteria, after revising colistin dosage to those predicted to achieve bactericidal activity in blood. We observed similar 28-day mortality rates with the higher dosing regimen (9 MIU loading dose followed by 9 MIU daily for patients with normal renal function). After adjustment by multivariate analysis and propensity score, the OR for mortality with high dosing was 1.07 (95% CI, .63-1.83) among 529 patients with a 28-day mortality of 40.6%. Similarly, we did not observe a difference in earlier mortality, nor in other clinical outcomes. Results were similar among patients with bacteremia, although only 24 bacteremic patients received high-dose colistin. Renal failure, with a creatinine level increase up to 3 times the baseline value on day 14, was significantly more common with high-dose colistin, as were seizures. There are no RCTs examining the effects of colistin dosing. Although it has been previously described that higher mean daily dosing is associated with nephrotoxicity [13] (as in our study), there is not much information on clinical effectiveness outcomes. Several studies assessed the association between dosing and clinical outcomes. Some have shown better outcomes with high dosing when assessing the outcome early, on days 7 or 14, and examining microbiological or clinical cure (Supplementary Table 2 ). Falagas et al found a significant inverse adjusted association between colistin dose and in-hospital mortality between the years 2000 and 2007 [14] . As dosing was not this study's primary exposure variable, it was not adjusted to renal function to account for the fact that low dosing is given to patients with renal failure. We calculated a corrected dose per patient based on renal function. Most of the patients in the Falagas et al study were treated with combination therapy, mainly with carbapenems, whereas in our study only 21.4% of patients received colistin-carbapenem combination therapy, usually for a possible polymicrobial infection. None of the more recent studies performed adjusted analyses for mortality. Two studies found lower crude mortality on day 7 with high dosing but no difference between the low-and high-dose regimens on day 28 [15, 16] . In the other studies, there was no difference in mortality [17, 18] .
There are limitations to our analysis, primarily the observational design. The fact that the exposure variable was mostly determined by the study period ( patients were treated with high dose only during the last study period after change of policy in participating hospitals) minimizes to an extent the selection of patients based on the exposure variable. However, it introduces another bias of comparison between periods. The epidemiology of carbapenem-resistant bacteria changed in Israel with control of the carbapanem-resistant enterobacteriaceae (CRE) epidemic [19, 20] , such that K. pneumoniae infections were significantly less common in the high-dose study period, whereas A. baumannii infections were most common in both periods. Probably the largest confounder for the dosing comparison, despite the period separation, was renal failure as an underlying disorder associated both with lower dosing (in both periods) and with mortality. Thus, this bias should have led to a superfluous advantage to higher dosing, which we did not observe. One hospital was added only in the second study period. However, we did not observe differences between patient and infection characteristics or mortality between hospitals; an analysis limited to b Assessed for patients not requiring hemodialysis at onset of treatment with renal function assessment available on day 14. Patients dying before day 14 without renal failure were also excluded, whereas those developing nephrotoxicity before death were included.
the hospital participating in both study periods showed similar results (data not shown). The comparison of superinfection rates and acquisition of colistin resistance might be affected by changing infection control practices. We could not assign patients to RIFLE criteria loss and end-stage renal failure, as most patients did not survive the length of follow-up necessary to fulfill these. Data on seizures and neuropathy relied on documentation of these events in the medical records; while neuropathy was probably underdiagnosed among these critically ill patients, we assume that seizures were not missed and were well documented in both study periods. Our analysis attempts to correlate bactericidal colistin concentrations with clinical effectiveness. However, we had no data on actual drug levels. In a concurrent RCT ongoing at both study centers, colistin levels were measured among participating patients receiving high-dose colistin adjusted to renal function (not included in this analysis) [9] . Preliminary analyses show high concentrations in general (>3-4 mg/L) and extreme variability between patients, despite standardized dosing [21] . Thus, factors other than dosing may underlie the concentrations achieved. Colistin MICs, available only in the second study period, were generally low. We presume that they were not higher and might have been lower in the first study period, which coincided with a CRE outbreak in Israel and the start of colistin use after decades of no systemic use [20] . The low colistin MICs and the data on colistin levels in participating hospitals might explain the lack of benefit of high dosing observed in our study.
Compiling the knowledge to date leads to confusion concerning the implications for clinical practice. Results from PK studies are variable with regard to the colistin dose required to achieve "therapeutic" colistin concentrations [4, 5] , and in reality we are unsure of the levels required for maximal effectiveness. Previous studies show that higher dosing might have some benefit in early microbiological and non-mortality-related clinical outcomes on day 7. However, both in our study and the previous studies, overall for the patient this does not seem to matter as 1-month mortality rates were not different with high or low dosing. Nephrotoxicity rates (albeit not end-stage renal failure) and seizures are more frequent with high-dose colistin [13, 22, 23] . While PK studies might reach a consensus on the required dosing regimen in different patient populations, it is clear that clinical studies will be needed to assess patient-relevant outcomes. An RCT comparing low-vs high-dose colistin will need a huge sample size to show a difference or noninferiority. Furthermore, larger, observational studies might enable a look into patient subgroups.
In summary, in a large cohort study, we found no association between PK-tailored colistin dosing targeting therapeutic colistin levels compared with lower doses, and 28-day all-cause mortality. Renal failure and seizures were significantly more frequent with high-dose colistin.
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